ArticleThe British journal of radiology2025
Radiomics-based explainable artificial intelligence to predict treatment response following lung stereotactic body radiation therapy.
Article in The British journal of radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Creating strong predictive models in oncology.Patterns (New York, N.Y.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo develop and validate a CT-based radiomic-clinical-dosimetric model to assess the treatment response of lung metastasis following stereotactic body radiation therapy (SBRT).
methodsEighty lung metastases treated with SBRT curative intent in a single institution were analysed. The treatment responses of lung lesions were categorized as a complete responding (CR) group vs a non-complete responding (NCR) group according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria. For each lesion, 107 features were extracted from the CT planning images. The least absolute shrinkage and selection operator (LASSO) was used for features selection. An eXtreme Gradient Boosting (XGBoost) model was trained and validated. Shapley additive explanations (SHAP) analysis was used to provide insights into the impact of each variable on the model's predictions.
resultsEight radiomic features, 1 dosimetric variable, and no clinical variables were identified by LASSO and used to build the XGBoost model. The model yielded areas under the curve (AUCs) of 0.897 (95% CI 0.860-0.935) and 0.864 (95% CI 0.803-0.924) in the training cohort and validation cohort, respectively. Skewness, surface-to-volume ratio, sphericity, and biological equivalent dose (BED10) were the most significant variables in predicting CR. The SHAP plots illustrated the feature's global and local impact to the model, explaining the model output in a clinician-friendly way.
conclusionThe integration of the XGBoost model with the SHAP strategy was able to assess lung lesions CR following SBRT, with the potential to assist clinicians in directing personalized SBRT strategies in an understandable manner. ADVANCES IN KNOWLEDGE: The explainable radiomics model we propose can better predict the treatment response of lung metastasis after SBRT and provide further guidance for clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.